Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating
2025-10-27 17:31:28 ET
I'm going to begin coverage of Genenta Science ( GNTA ) with a "Buy" rating and this is based on the stock climbing by 90% on Friday on the back of news that it had partnered its off-the-shelf lentiviral vector Plasmid DNA technology platform with ANEMOCYTE. This news lends credibility for it to advance its cell therapy for the treatment of patients with advanced solid tumors. Specifically, it is in the process of developing temferon as a cell therapy to treat patients with unmethylated MGMT (uMGMT) glioblastoma multiforme [GBM] in a phase 1/2a study. As a matter of fact, it has already released positive results from this ongoing early-stage trial using this therapy to treat these patients....
Read the full article on Seeking Alpha
For further details see:
Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating
NASDAQ: GNTA
GNTA Trading
12.03% G/L:
$2.0501 Last:
2,349,733 Volume:
$1.59 Open:
